Radiation Res & Translational Biology

辐射研究

基本信息

批准号：
9071322
负责人：
KAREN E KNUDSEN
金额：
$ 28.46万
依托单位：
THOMAS JEFFERSON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-01 至 2018-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9071322
关键词：
Address Basic Science Biochemistry Bioinformatics Biology Bypass Cancer Center Cancer Immunology Science Cancer Patient Clinical Clinical Data Clinical Investigator Clinical Research Clinical Trials Collaborations Combined Modality Therapy Data Diagnosis Diagnostic Drug Design Drug Targeting Faculty Funding Genotoxic Stress Goals Hypoxia Image Imaging Techniques Immune Tolerance Immune system Immunologic Surveillance Immunologics Immunology Injury Instruction Ionizing radiation Malignant Neoplasms Molecular Target Normal tissue morphology Peer Review Grants Physicians Pre-Clinical Model Process Publications Radiation Radiation therapy Research Research Personnel Resistance Scientist Staging Technology Testing Therapeutic Therapeutic Intervention Tissues Translating Translational Research Translations Work angiogenesis bench to bedside cancer cell cancer therapy clinical practice design effective therapy effectiveness research experience improved innovation killings member multidisciplinary neoplastic cell novel novel therapeutic intervention programs technology/technique therapy resistant tumor tumor growth tumor progression vaccine development

项目摘要

PROJECT SUMMARY (See instructions); The Radiation Research and Translational Biology, (RRTB) program goal is to improve combination radiation therapies by 1) designing and testing new molecular targets identified by mechanistic studies, and 2) addressing tumor resistance to therapy and bypass of immune surveillance, and 3) designing, assessing and improving technologies that diagnose, stage, and deliver therapies for cancer patients. Program members address these goals with multidisciplinary efforts in biochemistry, immunology, drug design, preclinical models, and clinical experience, to accelerate translation from bench to bedside. The Program has been strengthened by integration of members from the former Program in Cancer Immunology. The current RRTB program, comprised of 34 basic, translational and clinical investigators from eleven departments, thus combines basic and clinical research strengths to conduct bench to bedside research and can reverse translate clinical data to inform further translational innovations. This work is supported by 36 peer-reviewed grants totaling direct funds of $13.2 million ($5.3 million from NCI). The total number of publications generated by Program members from 2007 to 2012 is 543 of which 11% are Intra-programmmatic and 22% are Inter-programmatic, with 4.6% being both. The specific research themes ofthe RRTB Program are: (1) Improve RT therapies by defining and characterizing molecular targets for ionizing radiation and for combined therapies, vaccine development and BMT (2) Immune tolerance and strategies for immune surveillance. (3) Tumor resistance: Microenvironment, hypoxia and angiogenesis. (4) Protecting normal tissues: normal tissue injury/genotoxic stress. (5) Clinical translation of diagnostic and therapeutic innovations, and (6) Improving clinical practice: Biomedical/Bioinformatics and Comparitive Effectiveness Research (CER). This program will continually generate new collaborations, intra- and interprogrammatically, and fresh research directions with other research programs in the cancer center.

项目摘要（参见说明）；放射研究和转化生物学 (RRTB) 计划的目标是通过 1) 设计和测试通过机制研究确定的新分子靶标，以及 2) 解决肿瘤对治疗的耐药性和绕过免疫监视，以及 3) 改进组合放射治疗。，评估和改进为癌症患者诊断、分期和提供治疗的技术。计划成员通过生物化学、免疫学、药物设计、临床前模型和临床经验等多学科努力来实现这些目标，以加速从实验室到临床的转化。通过整合前癌症免疫学项目的成员，该项目得到了加强。目前的 RRTB 项目由来自 11 个部门的 34 名基础、转化和临床研究人员组成，因此结合了基础和临床研究优势，进行从实验室到临床的研究，并可以反向翻译临床数据，为进一步的转化创新提供信息。这项工作得到了 36 个同行评审的支持直接资助总额为 1,320 万美元（其中 530 万美元来自 NCI）。 2007 年至 2012 年计划成员发表的出版物总数为 543 份，其中 11% 为计划内出版物，22% 为计划间出版物，4.6% 为计划内出版物和计划间出版物。 RRTB 计划的具体研究主题是： (1) 通过定义和表征电离辐射和联合疗法、疫苗开发和 BMT 的分子靶点来改进 RT 疗法 (2) 免疫耐受和免疫策略监视。 (3)肿瘤抵抗：微环境、缺氧和血管生成。 (4)保护正常组织：正常组织损伤/基因毒性应激。 (5) 诊断和治疗创新的临床转化，以及 (6) 改善临床实践：生物医学/生物信息学和比较有效性研究 (CER)。该计划将不断产生新的项目内和项目间合作，以及癌症中心其他研究项目的新研究方向。